Suppr超能文献

人类树突状细胞对源自蘑菇和大麦的不同免疫调节多糖的反应。

Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley.

作者信息

Chan Wing Keung, Law Helen Ka Wai, Lin Zhi-Bin, Lau Yu Lung, Chan Godfrey Chi-Fung

机构信息

Department of Paediatrics and Adolescent Medicine, Hong Kong Jockey Club Clinical Research Center, Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.

出版信息

Int Immunol. 2007 Jul;19(7):891-9. doi: 10.1093/intimm/dxm061. Epub 2007 Jul 2.

Abstract

Polysaccharides derived from fungi and plants have been increasingly used as dietary supplement with therapeutic intention for cancer. However, whether these polysaccharides from different sources and structures can elicit similar immunological effects remain unknown. This study aims to investigate and compare the effects of selected groups of purified and crude polysaccharides on human dendritic cells (DCs), the most potent antigen-presenting cells. The selected polysaccharides were from Ganoderma lucidum [(GL) Lingzhi, Reishi], a medicinal mushroom commonly used by oriental; and barley glucan, a purified polysaccharide with known in vivo immunomodulating effect. We found that purified polysaccharides from GL mycelium could induce human PBMC proliferation and phenotypic and functional maturation of DCs with significant IL-12 and IL-10 production. Polysaccharides of GL spore and barley were both rather weak immunostimulator in vitro. In general, all these polysaccharides did not polarize T cells into either T(h)1 or T(h)2 or regulatory T cells, except for crude spore polysaccharides-treated DCs which could suppress T cell proliferation with IL-10 production. This study revealed the polysaccharides of different sources have different immune potency and effect on human immune cells including DCs. Our study also provides a reproducible biological platform for comparing the potential therapeutic effects of different herbal-derived polysaccharides in the future.

摘要

源自真菌和植物的多糖越来越多地被用作具有癌症治疗意图的膳食补充剂。然而,这些来自不同来源和结构的多糖是否能引发相似的免疫效应仍不清楚。本研究旨在调查和比较选定的纯化多糖组和粗多糖组对人类树突状细胞(DCs)的影响,DCs是最有效的抗原呈递细胞。选定的多糖来自灵芝(GL)(灵芝、瑞草),一种东方常用的药用蘑菇;以及大麦β-葡聚糖,一种具有已知体内免疫调节作用的纯化多糖。我们发现,来自灵芝菌丝体的纯化多糖可诱导人外周血单个核细胞增殖以及DCs的表型和功能成熟,并产生显著的白细胞介素-12和白细胞介素-10。灵芝孢子多糖和大麦多糖在体外均为较弱的免疫刺激剂。总体而言,除了经粗孢子多糖处理的DCs可通过产生白细胞介素-10抑制T细胞增殖外,所有这些多糖均未将T细胞极化为辅助性T细胞1型(Th1)或辅助性T细胞2型(Th2)或调节性T细胞。本研究揭示了不同来源的多糖对包括DCs在内的人类免疫细胞具有不同的免疫效力和作用。我们的研究还为未来比较不同草药来源多糖的潜在治疗效果提供了一个可重复的生物学平台。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验